vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare
June 01, 2022 06:54 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $25 million investment by G42 Investments AI Holding RSC...
vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update
May 12, 2022 07:45 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2022, and provided an update on the...
vTv Therapeutics Shares Updated Corporate Presentation
January 13, 2022 08:30 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Jan. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company committed to improving the quality of life for people with...
vTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations
December 06, 2021 17:19 ET
|
vTv Therapeutics Inc.
-Workforce reduction of 65% -Prioritization of lead program TTP399, a potentially transformative treatment for the reduction of hypoglycemic episodes in type 1 diabetes patients HIGH POINT, N.C.,...
vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update
November 09, 2021 08:30 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2021, and provided an update on the...
vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
October 12, 2021 07:30 ET
|
vTv Therapeutics Inc.
Study achieved primary endpoint of non-inferiority on measurement of key blood ketone levels Patients taking TTP399 reported no events of hypoglycemia, while four events of hypoglycemia were reported...
vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
September 23, 2021 16:30 ET
|
vTv Therapeutics Inc.
HPP737 exhibited favorable safety and tolerability profile, with no dose limiting gastrointestinal side effects Results build on data from previous multiple ascending dose study and support...
vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update
August 04, 2021 16:30 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2021, and provided an update on the...
vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737
June 29, 2021 07:30 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., June 29, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer
June 22, 2021 07:30 ET
|
vTv Therapeutics Inc.; Cantex Pharmaceuticals, Inc.
HIGH POINT, N.C. and WESTON, Fla., June 22, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (“vTv”, Nasdaq:VTVT) and Cantex Pharmaceuticals, Inc. (“Cantex”) today announced that they have entered...